Pfizer launches clinical trial of omicron-specific, COVID-19 vaccine
Added 01-25-22 09:03:02am EST - “Pfizer and BioNTech on Tuesday launched a clinical study to evaluate the safety and efficacy of a COVID-19 vaccine that targets omicron, the globally dominant variant.” - Washingtontimes.com
CLICK TO SHARE
Pfizer and BioNTech on Tuesday launched a clinical study to evaluate the safety and efficacy of a COVID-19 vaccine that targets omicron, the globally dominant variant.
Omicron’s spread has been so fast that it elbowed out variants, including delta. Scientists, though, aren’t sure if a specially tailored shot will be needed, or if it is best to stick with boosting existing products to cover a panoply of variants, especially if a new one takes omicron’s place at the top.
“While current research and real-world data show that boosters continue to provide a high level of protection against severe disease and hospitalization with omicron, we recognize the need to be prepared in the event this protection wanes over time and to potentially help address omicron and new variants in the future,” said Kathrin U. Jansen, senior vice president and head of vaccine research and development at Pfizer.
The study will be divided into three parts. The drugmaker said 615 people who received two doses of the Pfizer-BioNTech vaccine 90-180 days before enrollment will receive one or two doses of the omicron-specific vaccine.
Six hundred people who received three doses of the vaccine 90-180 days before the study will receive one shot of either the omicron vaccine or the existing vaccine.
If you don't see any comments yet, congrats! You get first comment. Be nice and have fun.
CLICK TO SHARE